Efficacy and Safety of Risankizumab in Hidradenitis Suppurativa: A Case Series
DOI:
https://doi.org/10.2340/actadv.v102.2926Keywords:
hidradenitis suppurativa, risankizumab, biologicsAbstract
Abstract is missing (Short communication)
Downloads
References
Jiang SW, Whitley MJ, Mariottoni P, Jaleel T, MacLeod AS. Hidradenitis suppurativa: host-microbe and immune pathogenesis underlie important future directions. JID Innov 2021; 1: 100001.
https://doi.org/10.1016/j.xjidi.2021.100001 DOI: https://doi.org/10.1016/j.xjidi.2021.100001
Kimball AB, Okun MM, Williams DA, Gottlieb AB, Papp KA, Zouboulis CC, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med 2016; 375: 422-434.
https://doi.org/10.1056/NEJMoa1504370 DOI: https://doi.org/10.1056/NEJMoa1504370
Kelly G, Hughes R, McGarry T, van den Born M, Adamzik K, Fitzgerald R, et al. Dysregulated cytokine expression in lesional and non lesional skin in hidradenitis suppurativa. Br J Dermatol 2015; 173: 1431-1439.
https://doi.org/10.1111/bjd.14075 DOI: https://doi.org/10.1111/bjd.14075
Schlapbach C, Hänni T, Yawalkar N, Hunger RE. Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol 2011; 65: 790-798.
https://doi.org/10.1016/j.jaad.2010.07.010 DOI: https://doi.org/10.1016/j.jaad.2010.07.010
Amat-Samaranch V, Agut-Busquet E, Vilarrasa E, Puig L. New perspectives on the treatment of hidradenitis suppurativa. Ther Adv Chronic Dis 2021; 12: 20406223211055920.
https://doi.org/10.1177/20406223211055920 DOI: https://doi.org/10.1177/20406223211055920
Montero-Vilchez T, Pozo-Román T, Sánchez-Velicia L, Vega-Gutiérrez J, Arias-Santiago S, Molina-Leyva A. Ustekinumab in the treatment of patients with hidradenitis suppurativa: multicenter case series and systematic review. J Dermatolog Treat 2022; 33: 348-353.
https://doi.org/10.1080/09546634.2020.1755008 DOI: https://doi.org/10.1080/09546634.2020.1755008
Sharon VR, Garcia MS, Bagheri S, Goodarzi H, Yang C, Ono Y, Maverakis E. Management of recalcitrant hidradenitis suppurativa with ustekinumab. Acta Derm Venereol 2012; 92: 320-321.
https://doi.org/10.2340/00015555-1229 DOI: https://doi.org/10.2340/00015555-1229
Blok JL, Li K, Brodmerkel C, Horvátovich P, Jonkman MF, Horváth B. Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum. Br J Dermatol 2016; 174: 839-846.
https://doi.org/10.1111/bjd.14338 DOI: https://doi.org/10.1111/bjd.14338
Kovacs M, Podda M. Guselkumab in the treatment of severe hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2019; 33: e140-e141.
https://doi.org/10.1111/jdv.15368 DOI: https://doi.org/10.1111/jdv.15368
Burzi L, Repetto F, Ramondetta A, Rozzo G, Licciardello M, Ribero S, et al. Guselkumab in the treatment of severe hidradenitis suppurativa, a promising role? Dermatol Ther 2021; 34: 14930.
https://doi.org/10.1111/dth.14930 DOI: https://doi.org/10.1111/dth.14930
Montero-Vilchez T, Martinez-Lopez A, Salvador-Rodriguez L, Arias-Santiago S, Molina-Leyva A. The use of guselkumab 100 mg every 4 weeks on patients with hidradenitis suppurativa and a literature review. Dermatol Ther 2020; 33: 13456.
https://doi.org/10.1111/dth.13456 DOI: https://doi.org/10.1111/dth.13456
Marques E, Arenberger P, Smetanová A, Gkalpakiotis S, Zimová D, Arenbergerová M. Successful treatment of recalcitrant hidradenitis suppurativa with risankizumab after failure of anti-tumour necrosis factor alpha. Br J Dermatol 2021; 184: 966-967.
https://doi.org/10.1111/bjd.19716 DOI: https://doi.org/10.1111/bjd.19716
Caposiena Caro RD, Pensa C, Lambiase S, Candi E, Bianchi L. Risankizumab effectiveness in a recalcitrant case of hidradenitis suppurativa after anti-TNF and anti-interleukin-17 failures. Dermatol Ther 2021; 34: 15116.
https://doi.org/10.1111/dth.15116 DOI: https://doi.org/10.1111/dth.15116
Licata G, Gambardella A, Buononato D, De Rosa A, Calabrese G, Pellerone S, et al. A case of moderate hidradenitis suppurativa and psoriasis successfully treated with risankizumab. Int J Dermatol 2021; 61: 126-129.
https://doi.org/10.1111/ijd.15704 DOI: https://doi.org/10.1111/ijd.15704
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2022 Federica Repetto, Lorenza Burzi, Simone Ribero, Pietro Quaglino, Paolo Dapavo
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
